Meet Our Scientific Advisors

 

Dr. michael tarantino, md

Dr. Tarantino has 25 years of experience in hematology, with seven years as the Founder, Medical Director and President of the Bleeding & Clotting Disorders Institute. For over two decades he has devoted his medical career to the management of bleeding and clotting disorders, as well as non-malignant hematology disorders. Dr. Tarantino also serves as the medical director of the Anticoagulation Consultation Service at St. Francis Medical Center and co- chairs the Anti-thrombosis subcommittee. Since 2008, Dr. Tarantino is also a tenured Professor of Pediatrics and Medicine at the University Of Illinois College Of Medicine in Peoria and is active in teaching medical students, residents and allied health professionals. More…

Screen Shot 2019-08-08 at 4.30.43 PM.png

Dr. glenn pierce, md

Dr. Glenn Pierce is currently an independent consultant, entrepreneur-in-residence at Third Rock Ventures and serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Glenn is also a director of Voyager Therapeutics and Global Blood Therapeutics, two publicly held biotechnology companies. More…

Screen Shot 2019-08-08 at 4.30.55 PM.png

Dr. steven pipe, md

Dr. Steven Pipe completed his undergraduate medical training at the University of Toronto, and his pediatric training at McMaster University in Hamilton, Ontario. He came to the University of Michigan in 1993 and completed his pediatric hematology and oncology training in 1996. Dr. Pipe is an Associate Professor of Pediatrics and Pathology and currently serves as Director of the Division of Pediatric Hematology and Oncology, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program and Director of the Special Coagulation Laboratory. His clinical interests include both bleeding and thrombotic disorders as well as congenital vascular anomalies. Dr. Pipe also directs a basic research lab investigating coagulation factor VIII and molecular mechanisms of hemophilia A. More…

 
Screen Shot 2019-08-09 at 11.55.42 AM.png

Dr. christopher walsh, md

Christopher E. Walsh, MD, PhD, is Associate Professor and Director of the Hemophilia Program in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York City. He received his PhD in Biochemistry from Wake Forest School of Medicine and his MD from Tulane University School of Medicine. He then completed an internship and a residency in Internal Medicine at North Carolina Memorial Hospital in Chapel Hill and a residency in Internal Medicine and a fellowship in Hematology at the National Institutes of Health in Bethesda, Maryland. Dr. Walsh is board-certified in Hematology and Internal Medicine. More…

Screen Shot 2019-08-12 at 8.59.29 PM.png

brendan hayes

Brendan Hayes is the Director of External Affairs at the National Hemophilia Foundation and leads NHF’s Gene Therapy Initiative which includes developing accurate, non-biased educational content on gene therapy, working with payers and policymakers to ensure patients have access to these groundbreaking therapies, and strengthening collaborations with national rare disease and patient advocacy organizations. More…

Screen Shot 2019-08-09 at 11.55.49 AM.png

Dr. michael wang, md

Dr. Michael Wang is a pediatric hematologist-oncologist in Aurora, Colorado and is affiliated with multiple hospitals in the area, including Children's Hospital Colorado and UCHealth University of Colorado Hospital. He is the Clinical Director for the Hemophilia Treatment Center in Denver, CO. He received his medical degree from the University of Rochester School of Medicine and Dentistry and has been in practice for more than 20 years. Dr. Wang is dedicated to advancing clinical coagulation, by leading a multidisciplinary team that focuses our advancing knowledge and innovation in caring for patients with bleeding and clotting disorders. He believes by combining clinical care, health care delivery improvement, patient engagement, clinical trials, and teaching, we aim to improve the lives of our patients throughout their entire lifespan. More…